Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 119

1.

Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer.

Di Mascolo D, Varesano S, Benelli R, Mollica H, Salis A, Zocchi MR, Decuzzi P, Poggi A.

Cancers (Basel). 2019 Dec 31;12(1). pii: E104. doi: 10.3390/cancers12010104.

2.

Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.

Benelli R, Barboro P, Costa D, Astigiano S, Barbieri O, Capaia M, Poggi A, Ferrari N.

Int J Mol Sci. 2019 Dec 3;20(23). pii: E6091. doi: 10.3390/ijms20236091.

3.

IFN-γ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade.

Pistillo MP, Carosio R, Banelli B, Morabito A, Mastracci L, Ferro P, Varesano S, Venè R, Poggi A, Roncella S.

Cell Mol Immunol. 2019 Jun 19. doi: 10.1038/s41423-019-0245-x. [Epub ahead of print] No abstract available.

PMID:
31217525
4.

Functional Interaction of Hypoxia-Inducible Factor 2-Alpha and Autophagy Mediates Drug Resistance in Colon Cancer Cells.

Saint-Martin A, Martínez-Ríos J, Castañeda-Patlán MC, Sarabia-Sánchez MA, Tejeda-Muñoz N, Chinney-Herrera A, Soldevila G, Benelli R, Santoyo-Ramos P, Poggi A, Robles-Flores M.

Cancers (Basel). 2019 May 30;11(6). pii: E755. doi: 10.3390/cancers11060755.

5.

Human Gut-Associated Natural Killer Cells in Health and Disease.

Poggi A, Benelli R, Venè R, Costa D, Ferrari N, Tosetti F, Zocchi MR.

Front Immunol. 2019 May 3;10:961. doi: 10.3389/fimmu.2019.00961. eCollection 2019. Review.

6.

Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects.

Bassani B, Baci D, Gallazzi M, Poggi A, Bruno A, Mortara L.

Cancers (Basel). 2019 Apr 1;11(4). pii: E461. doi: 10.3390/cancers11040461. Review.

7.

Serum osteopontin negatively impacts on intima-media thickness in patients with systemic lupus erythematosus.

Carbone F, Dallegri F, Montecucco F, Poggi A, Nobili FM, Cacciapaglia F, Afeltra A, Moccetti T, Colombo BM.

Eur J Clin Invest. 2019 May;49(5):e13089. doi: 10.1111/eci.13089. Epub 2019 Mar 3.

PMID:
30767212
8.

Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.

Mortara L, Balza E, Bruno A, Poggi A, Orecchia P, Carnemolla B.

Front Immunol. 2018 Dec 18;9:2905. doi: 10.3389/fimmu.2018.02905. eCollection 2018. Review.

9.

Design and Synthesis of Ionic Liquid-Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPI-Coated Gold Nanoparticles.

D'Andrea F, Nuti E, Becherini S, Cuffaro D, Husanu E, Camodeca C, De Vita E, Zocchi MR, Poggi A, D'Arrigo C, Cappello V, Gemmi M, Nencetti S, Chiappe C, Rossello A.

ChemMedChem. 2019 Mar 22;14(6):686-698. doi: 10.1002/cmdc.201800733. Epub 2019 Feb 14.

PMID:
30600908
10.

Immunomodulatory Properties of Mesenchymal Stromal Cells: Still Unresolved "Yin and Yang".

Poggi A, Zocchi MR.

Curr Stem Cell Res Ther. 2019;14(4):344-350. doi: 10.2174/1574888X14666181205115452. Review.

PMID:
30516112
11.

Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency.

Balza E, Carnemolla B, Orecchia P, Rubartelli A, Poggi A, Mortara L.

Curr Med Chem. 2018 Sep 4. doi: 10.2174/0929867325666180904121118. [Epub ahead of print]

PMID:
30182839
12.

Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes.

Camodeca C, Nuti E, Tosetti F, Poggi A, D'Arrigo C, Zocchi MR, Rossello A.

ChemMedChem. 2018 Oct 8;13(19):2119-2131. doi: 10.1002/cmdc.201800482. Epub 2018 Sep 12.

PMID:
30102846
13.

Corrigendum: Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures.

Varesano S, Zocchi MR, Poggi A.

Front Immunol. 2018 Jun 13;9:1343. doi: 10.3389/fimmu.2018.01343. eCollection 2018.

14.

Corrigendum: How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.

Poggi A, Varesano S, Zocchi MR.

Front Immunol. 2018 Jun 11;9:1342. doi: 10.3389/fimmu.2018.01342. eCollection 2018.

15.

Targeting the Epidermal Growth Factor Receptor Can Counteract the Inhibition of Natural Killer Cell Function Exerted by Colorectal Tumor-Associated Fibroblasts.

Costa D, Venè R, Benelli R, Romairone E, Scabini S, Catellani S, Rebesco B, Mastracci L, Grillo F, Minghelli S, Loiacono F, Zocchi MR, Poggi A.

Front Immunol. 2018 May 29;9:1150. doi: 10.3389/fimmu.2018.01150. eCollection 2018.

16.

Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures.

Varesano S, Zocchi MR, Poggi A.

Front Immunol. 2018 May 8;9:998. doi: 10.3389/fimmu.2018.00998. eCollection 2018. Erratum in: Front Immunol. 2018 Jun 13;9:1343.

17.

Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells.

Tosetti F, Venè R, Camodeca C, Nuti E, Rossello A, D'Arrigo C, Galante D, Ferrari N, Poggi A, Zocchi MR.

Oncoimmunology. 2018 Jan 19;7(5):e1421889. doi: 10.1080/2162402X.2017.1421889. eCollection 2018.

18.

How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.

Poggi A, Varesano S, Zocchi MR.

Front Immunol. 2018 Feb 19;9:262. doi: 10.3389/fimmu.2018.00262. eCollection 2018. Review. Erratum in: Front Immunol. 2018 Jun 11;9:1342.

19.

SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects.

Damonte P, Sociali G, Parenti MD, Soncini D, Bauer I, Boero S, Grozio A, Holtey MV, Piacente F, Becherini P, Sanguineti R, Salis A, Damonte G, Cea M, Murone M, Poggi A, Nencioni A, Del Rio A, Bruzzone S.

Bioorg Med Chem. 2017 Oct 15;25(20):5849-5858. doi: 10.1016/j.bmc.2017.09.023. Epub 2017 Sep 19.

PMID:
28958848
20.

The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.

Brizzolara A, Benelli R, Venè R, Barboro P, Poggi A, Tosetti F, Ferrari N.

Cancer Lett. 2017 Aug 1;400:9-17. doi: 10.1016/j.canlet.2017.04.025. Epub 2017 Apr 25.

PMID:
28450158

Supplemental Content

Loading ...
Support Center